Navigation Links
Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
Date:5/19/2011

nal of Clinical Oncology. "This drug happens to be just right for him."

Mr. Johnston's treatment with tamibarotene, which is considered 10 times more potent than all-trans retinoic acid, another retinoid commonly used to treat this type of leukemia, began in December 2009. He took the drug twice daily for 56 days, followed by a two-week break. Since then, Mr. Johnston has been taking the drug 28 days on, 28 off.

On April 18, he returned to UT Southwestern for a positron emission tomography (PET) scan, which showed his cancer had not relapsed for the fifth time.

"The type of acute leukemia he has is very rare. It's usually curable with current therapies, but as it relapses it becomes more resistant and harder to treat," said Dr. Collins.

Gambling on life, and success as a musician, doesn't scare the Alabama native who once dreamed of a professional basketball career. But cancer ended his NBA stint, which began when he won a spot on the Dallas Mavericks summer league roster during a Hoop It Up tournament in 2004.

Mr. Johnston didn't even know he had leukemia until that August, when he injured his leg in a pick-up game. He was diagnosed with compartment syndrome, a condition in which pressure in the muscle builds to dangerous levels. Following surgery, doctors were unable to control bleeding. They soon discovered that Mr. Johnston's body was riddled with advanced leukemia.

His treatment included chemotherapy, surgery and a bone marrow transplant. Mr. Johnston's type of leukemia, which affects soft tissues rather than blood and bone marrow, represents just 5 percent to 8 percent of acute myelogenous leukemia, the most common form of the disease.

Discouraged by failing treatments and the thought of his first bone marrow transplant, he nearly gave up hope. In 2006, a recommendation from a friend led him to Dr. Collins and UT Southwestern.

"When you achieve a life milestone that you're not supposed
'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. UCSF team discovers key to fighting drug-resistant leukemia
2. Most Leukemia Patients Recover From Chemo Brain After Transplant: Study
3. Agent selectively targets malignant B cells in chronic leukemia, study shows
4. Possible new approach to treating deadly leukemia in babies
5. New drug shows potential for treatment-resistant leukemia
6. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
7. Tracking down the origin of leukemia relapse
8. New approach to leukemia chemotherapy -- is a cure in sight?
9. UCSF researchers identify promising new treatment for childhood leukemia
10. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
11. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... to thwart tumor,s comeback , , WEDNESDAY, Jan. 21 ... cancer stem cells or "tumor-initiating cells" which, when targeted ... malignant. , The finding bolsters the theory that cancer ... are resistant to conventional therapies and responsible for tumor ...
... January 2009 - A new study conducted at the ... the University of Bologna, and published by Elsevier in ... http://www.elsevier.com/locate/cortex ) shows that, in confabulating patients, memory accuracy ... cognitive processes supporting adaptive behavior need attentional resources for ...
... Technical University of Catalonia (UPC) and Universitat Autnoma de ... (ESA) to design and carry out a scientific experiment ... between drugs and cells differ under these conditions. The ... Vaquer, with a doctorate in Medicine from UAB, and ...
... Erdman, A Cogdell,Spencer Company, a subsidiary of Cogdell ... broke ground earlier this week on two new medical ... , The two projects, a ... Jackson, Tennessee and a $1.75 million cancer center in,Mebane, ...
... 21 Amil,Participacoes S.A. (Bovespa: AMIL3) ("Amilpar"), informs its ... a meeting held today, approved the,payment of Interest on ... per,common share, corresponding to the total amount of R$ ... 2009, based on shareholders, position of,January 21, 2009. , ...
... & Friends Stage Show Kicks-off This Month Helping ... Raise Funds for Research. Autism Speaks, the ... yearlong partnership with Thomas & FriendsTM Live! On ... musical stage show produced by AEG ThemeSTAR and ...
Cached Medicine News:Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 2Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 3Health News:When less attention improves behavior 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 3Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 3Health News:Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 2Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 3Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 4Health News:Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town 5
(Date:9/30/2014)... Aileron Therapeutics, Inc. - Product Pipeline ... Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline Review ... Therapeutics, Inc.,s pharmaceutical research and development focus. ... therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, complete ... by drug target, mechanism of action (MoA), route ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: